Ensysce Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary

• Ensysce Biosciences Inc ENSC.OQ reported a quarterly adjusted loss of $1.39​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of $-8.25. The mean expectation of two analysts for the quarter was for a loss of $3.01 per share. Wall Street expected results to range from $-4.50 to $-1.53 per share.

• Revenue rose 331.7% to $1.32 million from a year ago; analysts expected zero.

• Ensysce Biosciences Inc's reported EPS for the quarter was a loss of $1.39​.

• Ensysce Biosciences Inc shares had fallen by 16.4% this quarter and lost 73.7% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 1% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• Wall Street's median 12-month price target for Ensysce Biosciences Inc is $26.23

This summary was machine generated from LSEG data May 16 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)